English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Two new studies have investigated novel treatments for patients with castration-resistant prostate cancer, focusing on immunotherapy and combined chemotherapy. A personalized peptide vaccine (PPV) provided a survival advantage when used alongside estramustine phosphate (EMP), and a combined chemotherapy regimen offered a high response rate in metastatic disease, albeit with only similar time-to-progression and survival results to docetaxel monotherapy.

Immunotherapy and combined chemotherapy for castration-resistant and metastatic disease